Condition
Immune Checkpoint Inhibitor-Related Myocarditis
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Completed1
Recruiting1
Not Yet Recruiting1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07278817Not Yet RecruitingPrimary
Monitoring and Rehabilitation for ICIACI Rehabilitation：A Cohort Study
NCT05699915Not ApplicableTerminated
Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors
NCT05934214Completed
EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database
NCT05598879Recruiting
Global Cardio Oncology Registry
Showing all 4 trials